These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)]. Jakse G Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186 [TBL] [Abstract][Full Text] [Related]
32. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder]. Tsukagoshi S Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724 [TBL] [Abstract][Full Text] [Related]
33. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177 [TBL] [Abstract][Full Text] [Related]
34. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321 [TBL] [Abstract][Full Text] [Related]
35. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Bassi P Surg Oncol; 2002 Jun; 11(1-2):77-83. PubMed ID: 12031870 [TBL] [Abstract][Full Text] [Related]
37. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757 [TBL] [Abstract][Full Text] [Related]
38. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin. Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616 [TBL] [Abstract][Full Text] [Related]